108852-43-3

Basic information

• Product Name: O-benzylferulic acid chloride
• Synonyms: O-benzylferulic acid chloride
• CAS NO: 108852-43-3
• Molecular Weight: 302.757
• Mol File: 108852-43-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: O-benzylferulic acid chloride(CAS DataBase Reference)
• NIST Chemistry Reference: O-benzylferulic acid chloride(108852-43-3)
• EPA Substance Registry System: O-benzylferulic acid chloride(108852-43-3)

Safety Data

• Hazardous Substances Data: 108852-43-3(Hazardous Substances Data)

Upstream product

• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 77795-22-3 4-benzyloxy-3-methoxycinnamic acid 
• 94475-61-3 (E)-3-(3-methoxy-4-benzyloxyphenyl)acrylic acid benzyl ester 
• 1135-24-6 (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid 

Downstream Products

• 94475-60-2 3-(O-benzylferulyl)-1,3-thiazolidine-2-thione 
• 1186073-36-8 (E)-3-(4-benzyloxy-3-methoxyphenyl)-N-[4-methyl-3-(4-pyridin-3-ylpyrimidin-2-ylamino)phenyl]acrylamide 
• 95686-90-1 N⁸-(4-hydroxy-3-methoxycinnamoyl)spermidine 
• 95687-20-0 (E)-N-[3-(4-Amino-butylamino)-propyl]-3-(4-hydroxy-3-methoxy-phenyl)-acrylamide 
• 89091-81-6 1-ethyl-1-ferulylputrescine 
• 124010-39-5 (E)-N-(4-Bromo-butyl)-3-(4-hydroxy-3-methoxy-phenyl)-acrylamide 
• 124010-38-4 (E)-N-(3-Bromo-propyl)-3-(4-hydroxy-3-methoxy-phenyl)-acrylamide 
• 77795-19-8 5-(4-benzyloxy-3-methoxyphenyl)-2E,4E-pentadienoic acid piperidine amide 
• 77795-21-2 (E)-3-[4-(benzyloxy)-3-methoxyphenyl]acrylaldehyde 
• 124010-36-2 (E)-3-(4-Benzyloxy-3-methoxy-phenyl)-N-(3-bromo-propyl)-acrylamide 
• 124010-37-3 (E)-3-(4-Benzyloxy-3-methoxy-phenyl)-N-(4-bromo-butyl)-acrylamide 

Relevant articles and documents

Efficient synthesis of 4-methylumbelliferyl dihydroferulate

A convenient four-step synthesis of 4-methylumbelliferyl dihydroferulate, starting from ferulic acid and 4-methylumbelliferone is described.

Synthesis, in vitro and in vivo antitumor activity of scopoletin-cinnamic acid hybrids

A series of hybrids of scopoletin and substituted cinnamic acid were designed, synthesized and evaluated in vitro and in vivo against five human tumor cell lines [MCF-7, MDA-MB-231, A549, HCT-116, and HeLa] with doxorubicin as the positive control. Compounds 17a, 17b, 17c and 17g exhibited potent cytotoxic activity. Especially, compound 17b displayed broad spectrum activity with IC50 values ranging from 0.249 μ1/4M to 0.684 μ1/4M. Moreover, in a preliminary pharmacological study, 17b not only remarkably induced cellular apoptosis, but also clearly induced A549 cells cycle arrest at S phase. In vivo study showed that 17b significantly suppressed tumor growth in a dose-dependent manner without causing the loss of the mean body weight of mice, which was superior to doxorubicin. These preliminary results indicate that 17b is an optimal anti-cancer leading compound and merit further structural modification.

Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells

A series of novel 2-phenylaminopyrimidine (PAP) derivatives structurally related to STI-571 were designed and synthesized. The abilities of these compounds to inhibit proliferation were tested in human chronic myeloid leukemia K562 cells. (E)-3-(2-bromophenyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)phenyl]acrylamide( 12d) was the most effective cell growth inhibitor and was 3-fold more potent than STI-571.